Deutsche Bank AG Makes New Investment in Emergent Biosolutions Inc. $EBS

Deutsche Bank AG bought a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 189,918 shares of the biopharmaceutical company’s stock, valued at approximately $1,592,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Pacer Advisors Inc. bought a new position in shares of Emergent Biosolutions during the 1st quarter worth approximately $3,454,000. Dimensional Fund Advisors LP grew its holdings in shares of Emergent Biosolutions by 22.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock valued at $22,884,000 after acquiring an additional 504,553 shares in the last quarter. Evolve Private Wealth LLC bought a new position in shares of Emergent Biosolutions in the first quarter valued at approximately $546,000. Renaissance Technologies LLC increased its position in shares of Emergent Biosolutions by 13.7% during the first quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock valued at $5,445,000 after acquiring an additional 78,900 shares during the last quarter. Finally, Morse Asset Management Inc increased its position in shares of Emergent Biosolutions by 11.0% during the second quarter. Morse Asset Management Inc now owns 208,044 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 20,580 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on EBS shares. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings raised Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. HC Wainwright lowered their target price on Emergent Biosolutions from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Emergent Biosolutions currently has a consensus rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Stock Performance

NYSE:EBS opened at $5.92 on Friday. The company has a market capitalization of $303.52 million, a P/E ratio of -1.67 and a beta of 2.35. The business has a fifty day simple moving average of $6.88 and a two-hundred day simple moving average of $8.08. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. Emergent Biosolutions Inc. has a 1 year low of $4.36 and a 1 year high of $14.06.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. On average, analysts expect that Emergent Biosolutions Inc. will post -4.61 earnings per share for the current year.

Insider Buying and Selling

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president owned 159,098 shares in the company, valued at $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.